News – Page 991 – Endpoints News

Sanofi is concentrating its forces in Cambridge hub, inking a massive lease for 2,700 staffers

7 years ago

FibroGen, AstraZeneca score China approval for anemia drug ahead of pivotal US data

7 years ago

FDA names new No. 2 to replace retiring Sherman

7 years ago

Vertex CFO Thomas Graney exits abruptly; Eli Lilly touts a head-to-head win over Humira

7 years ago

Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest

7 years ago

Novo Nordisk grabs a $486M buyout option on an anti-apoC3 antibody for its cardio R&D group

7 years ago

Tossed in a storm of controversies, Proteostasis finds shelter in $100M cash Roche deal — shares surge

7 years ago

Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own

7 years ago

Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash

7 years ago

Harvard prof Omid Farokhzad heads west, setting up a new Bay Area biotech on a mission to start a revolution in ...

7 years ago

European VC firm Kurma sets its sights on €150 million fund, its biggest ever

7 years ago

Tesaro execs split $304M windfall from $5.1B GlaxoSmithKline buyout

7 years ago

Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets

7 years ago

Anatomy of a long-delayed biotech buyout: With its stock price beaten down, abandoned by potential bidders, Tesaro ...

7 years ago

Software developer Synthace raises $25.6M to realize 'computer aided biology'

7 years ago

Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey exits Argos for Novadip; Frank Czerwiec is the new CMO at ...

7 years ago

Plowing ahead after its latest setback, Axovant nabs two assets to beef up gene therapy pipeline

7 years ago

AstraZeneca wants a do-over on MYSTIC combo data. But a changeup in focus won’t end the death watch on this pairing

7 years ago

Under pressure, drugmakers dilute price hikes, but nothing is set in stone just yet — report

7 years ago

Two years and $78M later, Amgen washes its hands of Advaxis' I/O drug — and shares plummet

7 years ago

This is the FDA’s year to shine, but can biopharma keep up as regulators continue to rev up chart-topping numbers?

7 years ago

Mylan claims win in Lantus patent battle, but legal war with Sanofi is far from over

7 years ago

Lilly, Incyte's baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO

7 years ago

Biogen shrugs off $1B-plus gene therapy pact after PhI/II implosion — AGTC shares crater

7 years ago

First page Previous page 988 989 990991992 993 994 Next page Last page